Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nucleophosmin status may influence the therapeutic decision in de novo acute myeloid leukemia with normal karyotype.
Bardet V, Costa LD, Elie C, Malinge S, Demur C, Tamburini J, Lefebvre PC, Witz F, Lioure B, Jourdan E, Pigneux A, Ifrah N, Attal M, Dreyfus F, Mayeux P, Lacombe C, Bennaceur-Griscelli A, Bernard OA, Bouscary D, Récher C; GOELAMS: Groupe Ouest Est d'etude des Leucémies et des Autres Maladies du Sang. Bardet V, et al. Leukemia. 2006 Sep;20(9):1644-6. doi: 10.1038/sj.leu.2404294. Epub 2006 Jun 22. Leukemia. 2006. PMID: 16791266 No abstract available.
Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients.
Tamburini J, Elie C, Bardet V, Chapuis N, Park S, Broët P, Cornillet-Lefebvre P, Lioure B, Ugo V, Blanchet O, Ifrah N, Witz F, Dreyfus F, Mayeux P, Lacombe C, Bouscary D. Tamburini J, et al. Among authors: bardet v. Blood. 2007 Aug 1;110(3):1025-8. doi: 10.1182/blood-2006-12-061283. Epub 2007 Apr 10. Blood. 2007. PMID: 17426258 Free article. Clinical Trial.
Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways.
Tamburini J, Chapuis N, Bardet V, Park S, Sujobert P, Willems L, Ifrah N, Dreyfus F, Mayeux P, Lacombe C, Bouscary D. Tamburini J, et al. Among authors: bardet v. Blood. 2008 Jan 1;111(1):379-82. doi: 10.1182/blood-2007-03-080796. Epub 2007 Sep 18. Blood. 2008. PMID: 17878402 Free article.
Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia.
Park S, Chapuis N, Tamburini J, Bardet V, Cornillet-Lefebvre P, Willems L, Green A, Mayeux P, Lacombe C, Bouscary D. Park S, et al. Among authors: bardet v. Haematologica. 2010 May;95(5):819-28. doi: 10.3324/haematol.2009.013797. Epub 2009 Nov 30. Haematologica. 2010. PMID: 19951971 Free PMC article. Review.
69 results